Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2020 – Multiple Myeloma
ASH 2020 – Multiple Myeloma
APOLLO: Daratumumab + Pomalidomide and Dexamethasone versus Pomalidomide and Dexamethasone Alone in Patients with RRMM
ASH 2020 – Multiple Myeloma
Compared with pomalidomide and dexamethasone (Pd) alone, daratumumab + Pd reduced the risk for disease progression and death without additional safety signals for patients with RRMM who had received ≥1 prior lines of therapy, including lenalidomide and a proteasome inhibitor.
Read More ›
Idecabtagene Vicleucel, a BCMA-Directed CAR T-Cell Therapy, in Patients with RRMM: CRB-401 Study Updates
ASH 2020 – Multiple Myeloma
Updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the BCMA-directed CAR T-cell therapy, idecabtagene vicleucel, in RRMM at target dose levels of ≥150 × 106 CAR+ T-cells.
Read More ›
CARTITUDE-1: Ciltacabtagene Autoleucel, a BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy, in RRMM
ASH 2020 – Multiple Myeloma
Preliminary results from the phase 1b/2 CARTITUDE-1 study reveal early, deep, and durable responses and a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM.
Read More ›
FORTE Trial: Analysis of Survival in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma
ASH 2020 – Multiple Myeloma
In the FORTE trial, patients with NDMM who were transplant-eligible experienced significantly improved progression-free survival with carfilzomib + lenalidomide + dexamethasone (KRd) induction-ASCT-KRd consolidation versus either 12 KRd cycles or carfilzomib + cyclophosphamide + dexamethasone (KCd) induction-ASCT-KCd consolidation.
Read More ›
Isatuximab + Pomalidomide and Dexamethasone in Frail Patients with RRMM: ICARIA-MM Subgroup Analysis
ASH 2020 – Multiple Myeloma
The ICARIA-MM investigators studied the effects of isatuximab + pomalidomide and dexamethasone in the subgroup of frail patients with RRMM, and results support use of the regimen among these patients.
Read More ›
Minimal Residual Disease After Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
ASH 2020 – Multiple Myeloma
Interim results from a phase 2 trial exploring the response to ixazomib, lenalidomide, and dexamethasone induction followed by a single autologous stem-cell transplantation, IRd consolidation, and risk-based maintenance showed an overall response rate of 93%.
Read More ›
Cobimetinib as Monotherapy and in Combination with Venetoclax with or without Atezolizumab in Patients with RRMM
ASH 2020 – Multiple Myeloma
Preliminary results from this phase 1b/2 study of cobimetinib alone or plus venetoclax, with or without atezolizumab, in patients with RRMM show manageable toxicity, moderate efficacy overall, and higher efficacy for t(11;14) patients.
Read More ›
BFCR4350A, a FcRH5 x CD3 T-Cell–Engaging Bispecific Antibody, in Patients with RRMM: Preliminary Clinical Activity and Safety
ASH 2020 – Multiple Myeloma
Preliminary results from the GO39775 study show promising efficacy and manageable toxicity for BFCR4350A as monotherapy in patients with RRMM with high-risk cytogenetics, triple-class refractory disease, and/or prior exposure to anti-CD38 monoclonal antibodies, CAR T-cells, or antibody–drug conjugates.
Read More ›
Ixazomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
ASH 2020 – Multiple Myeloma
The interim results from a phase 2 trial examining the response to ixazomib, lenalidomide, and dexamethasone induction in newly diagnosed, transplant-eligible patients showed an overall response rate of 93%.
Read More ›
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
ASH 2020 – Multiple Myeloma
Preliminary results from a phase 2 study of isatuximab in patients with amyloid light-chain (AL) amyloidosis who were previously treated showed encouraging efficacy and a good safety profile.
Read More ›
Page 1 of 3
1
2
3
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us